Novartis PKC412 Receives Breakthrough Therapy Designation from FDA for Newly-diagnosed FLT3-mutated AML
February 19, 2016 at 04:31 AM EST
Novartis (NYSE: NVS) announced today that the United States Food and Drug Administration (FDA) has granted Breakthrough Therapy ...
